Tel Aviv Sourasky Medical Center

Oxular Doses First Patients in OXEYE Phase 2 Clinical Trial of Suprachoroidal OXU-001 as a Long-Acting Treatment for Diabetic Macular Edema

Retrieved on: 
Tuesday, October 24, 2023

“We are thrilled to have started dosing patients with suprachoroidal OXU-001 in our OXEYE clinical trial, which will evaluate the potential for once-a-year treatment by leveraging our Oxusphere™ sustained-release technology.

Key Points: 
  • “We are thrilled to have started dosing patients with suprachoroidal OXU-001 in our OXEYE clinical trial, which will evaluate the potential for once-a-year treatment by leveraging our Oxusphere™ sustained-release technology.
  • OXEYE builds on the positive clinical experience to date with our Oxulumis® illuminated microcatheter for in-clinic posterior suprachoroidal delivery,” said Dr. Friedrich Asmus, MD, Chief Medical Officer of Oxular.
  • We look forward to clinical data from the OXEYE trial next year.”
    OXU-001 is dexamethasone formulated in a novel biodegradable drug preparation known as Oxuspheres™.
  • The OXEYE trial is a two-part, randomized Phase 2 trial in patients with DME that is designed to evaluate a single administration of suprachoroidal OXU-001 over 52 weeks.

RG6501 (OpRegen®) Phase 1/2a Results Show Evidence of Rapid Improvement of Outer Retinal Structure in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Retrieved on: 
Thursday, October 5, 2023

RG6501 (OpRegen) is a suspension of human allogeneic retinal pigmented epithelial (RPE) cells currently in development for the treatment of GA secondary to age-related macular degeneration (AMD).

Key Points: 
  • RG6501 (OpRegen) is a suspension of human allogeneic retinal pigmented epithelial (RPE) cells currently in development for the treatment of GA secondary to age-related macular degeneration (AMD).
  • OpRegen subretinal delivery has the potential to counteract RPE cell loss in areas of GA lesions by supporting retinal cell health and improving retinal structure and function.
  • “We are extremely pleased to see these additional observations of rapid improvements to outer retinal structure in the initial clinical study of OpRegen.
  • Durability of retinal structure improvements beyond the 12-month primary endpoint is still being evaluated in other patients.

Briya Raises $11.5M Series A, Accelerates U.S. Rollout of Blockchain-Secured Data Exchange Platform to Enhance Collaboration Between Hospitals and Life Sciences

Retrieved on: 
Tuesday, September 19, 2023

NEW YORK, Sept. 18, 2023 /PRNewswire/ -- Briya, an end-to-end healthcare data exchange platform, today announced completion of an $11.5 million Series A round of financing, bringing the company's total funding to $17 million. The round was led by Team8, includes existing investors Insight Partners, Amiti Ventures and Innocare Health Investments, and is joined by the George Kaiser Family Foundation.

Key Points: 
  • The company's scalable data exchange platform enables hospitals to capitalize on their patient data.
  • The Briya platform connects clinics and hospitals with academic and pharmaceutical research teams, addressing the primary challenges faced by organizations in the collection and exchange of healthcare data.
  • The highly secured data exchange empowers hospitals to effectively utilize their health data and safely share it, in compliance with all regulatory guidelines.
  • "We expect to see Briya adopted as a scalable data exchange solution in institutes, hospitals, and organizations across the U.S. in the near future."

SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome

Retrieved on: 
Thursday, September 7, 2023

TEL AVIV, Israel, Sept. 07, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, today announced the initiation of its Phase IIb Clinical Trial for its proprietary SCI-110 for the treatment of Tourette Syndrome (“TS”) at the Tel Aviv Sourasky Medical Center in Israel (“Sourasky”).

Key Points: 
  • The trial is based on the positive data results received from the single arm Yale School of Medicine study using SCI-110 for TS.
  • "The initiation of our Phase IIb Clinical Trial at Sourasky, the Israeli site, is a major milestone towards commercializing our proprietary SCI-110 for TS patients.
  • TS in adults can be a debilitating disorder for which current treatments result in limited benefits.
  • The patients will be randomized at a 1:1 ratio to receive either SCI-110 or a SCI-110-matched placebo.

RG6501 (OpRegen®) Phase 1/2a Additional Results to Be Featured at 23rd EURETINA Congress

Retrieved on: 
Wednesday, September 13, 2023

The meeting will be held in the RAI Amsterdam, The Netherlands from October 5-8, 2023.

Key Points: 
  • The meeting will be held in the RAI Amsterdam, The Netherlands from October 5-8, 2023.
  • RG6501 (OpRegen) is a suspension of human allogeneic retinal pigmented epithelial (RPE) cells currently in development for the treatment of GA secondary to age-related macular degeneration (AMD).
  • OpRegen subretinal delivery has the potential to counteract RPE cell loss in areas of GA lesions by supporting retinal cell health and improving retinal structure and function.
  • It is being developed under an exclusive worldwide collaboration between Lineage, Roche, and Genentech, a member of the Roche Group, and is currently being evaluated in a Phase 2a clinical study in patients with GA secondary to AMD (ClinicalTrials.gov Identifier: NCT05626114 ).

Duality Technologies joins the fight against cancer with a new secure data collaboration toolkit enabling analytics and AI on Oncological Real-World Data

Retrieved on: 
Tuesday, August 15, 2023

HOBOKEN, N.J., Aug. 15, 2023 /PRNewswire/ -- Several of the world's most prestigious medical research organizations have partnered with Duality Technologies, the leader in secure data collaboration for enterprises and government agencies, to deliver a major breakthrough in sharing Real-World patient data securely and efficiently to advance medical research and improve oncological patient outcomes.

Key Points: 
  • This data is used to generate Real-World Evidence (RWE), which is essential in the development and success of treatments.
  • To reach sufficiently large cohorts of patients for research, and to enrich the data by linking data sets, medical centers must often collaborate with other organizations.
  • This data collaboration challenge hinders progress in medical research, negatively affecting the pace at which new potentially life-saving cancer treatments are introduced to the public.
  • Our joint study with Duality aimed and verified the accuracy of statistical oncology endpoints when done through encrypted data.

Fat Burning During Exercise Varies Widely Between Individuals; Study reveals limitations of commercial exercise machines

Retrieved on: 
Friday, August 11, 2023

NEW YORK, Aug. 11, 2023 /PRNewswire-PRWeb/ -- The best heart rate for burning fat differs for each individual and often does not align with the "fat burning zone" on commercial exercise machines, Icahn School of Medicine at Mount Sinai researchers report.

Key Points: 
  • The best heart rate for burning fat differs for each individual and often does not align with the "fat burning zone" on commercial exercise machines, Icahn School of Medicine at Mount Sinai researchers report.
  • NEW YORK, Aug. 11, 2023 /PRNewswire-PRWeb/ -- The best heart rate for burning fat differs for each individual and often does not align with the "fat burning zone" on commercial exercise machines, Icahn School of Medicine at Mount Sinai researchers report.
  • "People with a goal of weight or fat loss may be interested in exercising at the intensity which allows for the maximal rate of fat burning.
  • "We hope that this work will inspire more individuals and trainers to utilize clinical exercise testing to prescribe personalized exercise routines tailored to fat loss.

The Silverstein Foundation Launches Post-Doctoral Fellowship Program to Fund Novel Research for Parkinson’s Disease in GBA Mutation Carriers

Retrieved on: 
Thursday, July 20, 2023

The Silverstein Foundation for Parkinson’s with GBA (“Silverstein Foundation”) today announced the creation of a two-year, post-doctoral fellowship program that will fund eleven scientists engaged in cutting-edge research on Parkinson’s disease in GBA mutation carriers (GBA-PD) in academic and hospital-based laboratories around the world.

Key Points: 
  • The Silverstein Foundation for Parkinson’s with GBA (“Silverstein Foundation”) today announced the creation of a two-year, post-doctoral fellowship program that will fund eleven scientists engaged in cutting-edge research on Parkinson’s disease in GBA mutation carriers (GBA-PD) in academic and hospital-based laboratories around the world.
  • “The goal of this two-year program is to fund the next generation of elite researchers who will devote their time to finding novel, diverse approaches to analyze, prevent and treat GBA-PD,” said Jonathan Silverstein, founder of the Silverstein Foundation and a retired Managing Partner and former Co-Head of Private Equity at OrbiMed.
  • Silverstein added, “These researchers will meet regularly to collaborate and share findings with each other.
  • Furthermore, these findings will be made public to the broader GBA-PD community through publications and presentations at scientific conferences worldwide.

SciSparc Receives Approval to Conduct Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome in Germany

Retrieved on: 
Friday, June 30, 2023

TEL AVIV, Israel, June 30, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced it has been granted an approval from the Federal Institute for Drugs and Medical Devices in Germany (“BfArM”) for its Phase IIb clinical trial to use SCI-110 for treating adults with Tourette Syndrome ("TS") at the Hannover Medical School in Hannover, Germany.

Key Points: 
  • The Company has already secured the Institutional Review Board (“IRB) approvals from all three clinical sites as well as the Israeli Ministry of Health's approval for the clinical trial at Sourasky.
  • "We are excited to announce that SciSparc has received another official approval to embark on its Phase IIb Clinical Trial for SCI-110, aimed at treating TS, in Germany.
  • This Phase IIb Clinical Trial will enable us to rigorously evaluate the safety and efficacy of SCI-110, and we believe will further solidify its potential as a game-changing therapy."
  • The patients will be randomized in a 1:1 ratio to receive either SCI-110 or a SCI-110-matched placebo.

SciSparc Announces IRB Approval to Conduct its Phase IIb Trial in Tourette Syndrome

Retrieved on: 
Wednesday, June 21, 2023

TEL AVIV, Israel, June 21, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced it has received Institutional Review Board (IRB) approval for its Phase IIb clinical trial for SCI-110 in subjects suffering from Tourette Syndrome ("TS").

Key Points: 
  • TEL AVIV, Israel, June 21, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced it has received Institutional Review Board (IRB) approval for its Phase IIb clinical trial for SCI-110 in subjects suffering from Tourette Syndrome ("TS").
  • The objective of this Phase IIb randomized, multi-national, multi-center, double-blind, placebo controlled cross-over trial is to evaluate the efficacy, safety and tolerability of SciSparc's proprietary drug candidate SCI-110 in adults with TS (between 18 and 65 years of age).
  • Previously, SciSparc announced the Hannover Medical School in Hannover, Germany, and the Tel Aviv Sourasky Medical Center in Tel Aviv, Israel as medical center trial sites of excellence.
  • "We are excited to receive IRB approval for the trial from Yale University School of Medicine, which marks the achievement of another milestone towards the initiation of our Phase IIb clinical trial with TS subjects," stated SciSparc’s Chief Executive Officer, Oz Adler.